NEW YORK (GenomeWeb News) – SRI International and Spyglass Technologies today announced an exclusive licensing deal to commercialize SRI's underwater mass spectrometry technology.

The agreement calls for St. Petersburg, Fla.-based Spyglass to apply SRI's in situ membrane introduction mass spec (MIMS) technology to "a broad range of commercial, research, and government applications." Additionally, Spyglass will bundle the MIMS device with other underwater sensors, and the partners will continue collaborating on applications of the technology for other markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.